What is Tempest Therapeutics Inc's earnings per share (EPS)?

Tempest Therapeutics Inc (TPST) reported diluted earnings per share of $-6.33 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Tempest Therapeutics Inc Financials

TPST

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Tempest Therapeutics Inc (TPST) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Tempest Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.64x

For every $1 of reported earnings, Tempest Therapeutics Inc generates $0.64 in operating cash flow (-$26.8M OCF vs -$41.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-128.4x

Tempest Therapeutics Inc earns $-128.4 in operating income for every $1 of interest expense (-$26.6M vs $207K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$26.3M

YoY+36.8%

Tempest Therapeutics Inc's EBITDA was -$26.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.8% from the prior year.

Net Income

-$41.8M

YoY+0.0%

Tempest Therapeutics Inc reported -$41.8M in net income in fiscal year 2025. This represents an increase of 0.0% from the prior year.

EPS (Diluted)

$-6.33

Tempest Therapeutics Inc earned $-6.33 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 322.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$27.3M

YoY+18.5%

Tempest Therapeutics Inc generated -$27.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 18.5% from the prior year.

Cash & Debt

$7.7M

YoY-74.5%

5Y CAGR-16.4%

10Y CAGR-15.8%

Tempest Therapeutics Inc held $7.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

14M

Tempest Therapeutics Inc had 14M shares outstanding in fiscal year 2025. This represents an increase of 324.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-2092150.0%

YoY-2091931.2pp

10Y CAGR-2092092.3pp

Tempest Therapeutics Inc's ROE was -2092150.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2091931.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$12.6M

YoY-55.7%

5Y CAGR-2.6%

10Y CAGR-3.7%

Tempest Therapeutics Inc invested $12.6M in research and development in fiscal year 2025. This represents a decrease of 55.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$435K

YoY+0.0%

5Y CAGR+54.1%

10Y CAGR-22.0%

Tempest Therapeutics Inc invested $435K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

TPST Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$12.6M-55.7%	$28.5M+62.7%	$17.5M-22.3%	$22.5M+31.2%	$17.2M+19.3%	$14.4M
SG&A Expenses	$14.0M+3.1%	$13.6M+16.2%	$11.7M-3.7%	$12.1M+23.4%	$9.8M+100.0%	$4.9M
Operating Income	-$26.6M+36.8%	-$42.0M-44.1%	-$29.2M+15.8%	-$34.6M-28.4%	-$27.0M-39.8%	-$19.3M
Interest Expense	$207K-84.3%	$1.3M-9.2%	$1.4M-10.4%	$1.6M+26.2%	$1.3M	$0
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$41.8M0.0%	-$41.8M-41.9%	-$29.5M+17.4%	-$35.7M-26.2%	-$28.3M-47.3%	-$19.2M
EPS (Diluted)	$-6.33	$-1.50	$-1.91+38.2%	$-3.09+58.6%	$-7.47	$-41.03

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$570K-85.3%	$3.9M-49.2%	$7.6M	N/A	$7.6M+29.5%	$5.8M+34.5%	$4.3M	N/A
SG&A Expenses	$3.0M-26.1%	$4.1M+23.8%	$3.3M	N/A	$3.0M-20.1%	$3.7M+3.1%	$3.6M	N/A
Operating Income	-$3.6M+54.8%	-$8.0M+27.2%	-$10.9M	N/A	-$10.6M-10.1%	-$9.6M-20.2%	-$8.0M	N/A
Interest Expense	$0-100.0%	$46K-71.4%	$161K	N/A	$329K-11.6%	$372K+1.1%	$368K	N/A
Income Tax	$0	$0	$0	N/A	$0	$0	$0	N/A
Net Income	-$3.5M+55.4%	-$7.9M+27.5%	-$10.9M	N/A	-$10.6M-10.3%	-$9.6M-21.1%	-$7.9M	N/A
EPS (Diluted)	$-0.79+61.8%	$-2.07	$-3.16	N/A	$-5.32+3.6%	$-5.52-19.5%	$-4.62	N/A

TPST Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$16.9M-59.2%	$41.5M-19.6%	$51.6M+12.0%	$46.1M-37.1%	$73.2M+220.3%	$22.9M
Current Assets	$8.3M-73.7%	$31.5M-22.0%	$40.4M+22.5%	$33.0M-52.2%	$69.0M+247.9%	$19.8M
Cash & Equivalents	$7.7M-74.5%	$30.3M-22.8%	$39.2M+25.6%	$31.2M-39.7%	$51.8M+175.4%	$18.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$16.9M-24.3%	$22.4M-10.0%	$24.8M-11.2%	$28.0M-24.6%	$37.1M-59.5%	$91.7M
Current Liabilities	$3.3M-76.7%	$14.2M+51.1%	$9.4M+29.3%	$7.3M-63.7%	$20.0M+521.5%	$3.2M
Long-Term Debt	N/A	$0-100.0%	$6.3M-39.6%	$10.4M-31.2%	$15.1M	$0
Total Equity	$2K-100.0%	$19.1M-28.5%	$26.8M+47.8%	$18.1M-49.9%	$36.1M+152.5%	-$68.8M
Retained Earnings	-$233.4M-12.7%	-$207.1M-25.3%	-$165.3M-21.7%	-$135.8M-35.7%	-$100.1M-39.4%	-$71.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$17.1M-30.0%	$24.5M-23.9%	$32.2M-22.5%	$41.5M+22.6%	$33.8M-19.8%	$42.2M-5.0%	$44.4M-14.0%	$51.6M
Current Assets	$8.1M-46.3%	$15.1M-32.7%	$22.4M-28.7%	$31.5M+33.6%	$23.6M-25.3%	$31.5M-5.8%	$33.5M-17.0%	$40.4M
Cash & Equivalents	$7.5M-47.4%	$14.3M-33.6%	$21.5M-28.9%	$30.3M+36.9%	$22.1M-28.9%	$31.1M-3.7%	$32.3M-17.6%	$39.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.8M-26.7%	$14.7M-30.1%	$21.0M-6.0%	$22.4M-0.1%	$22.4M-11.3%	$25.2M+6.2%	$23.7M-4.4%	$24.8M
Current Liabilities	$3.5M-50.6%	$7.1M-45.8%	$13.2M-7.3%	$14.2M+1.8%	$14.0M-4.0%	$14.6M+36.2%	$10.7M+13.6%	$9.4M
Long-Term Debt	N/A	N/A	$4.2M	$0	$0-100.0%	$2.0M-51.5%	$4.1M-33.9%	$6.3M
Total Equity	$6.3M-35.1%	$9.8M-12.1%	$11.1M-41.8%	$19.1M+66.9%	$11.5M-32.4%	$16.9M-17.9%	$20.6M-22.9%	$26.8M
Retained Earnings	-$229.3M-1.6%	-$225.8M-3.6%	-$218.0M-5.2%	-$207.1M-7.1%	-$193.3M-5.8%	-$182.7M-5.5%	-$173.2M-4.8%	-$165.3M

TPST Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$26.8M+18.8%	-$33.0M-20.7%	-$27.4M+12.0%	-$31.1M-19.7%	-$26.0M-36.5%	-$19.0M
Capital Expenditures	$435K0.0%	$435K+155.9%	$170K-69.8%	$562K+316.3%	$135K+170.0%	$50K
Free Cash Flow	-$27.3M+18.5%	-$33.5M-21.6%	-$27.5M+13.0%	-$31.6M-21.2%	-$26.1M-36.8%	-$19.1M
Investing Cash Flow	-$435K0.0%	-$435K-155.9%	-$170K+69.8%	-$562K-479.4%	-$97K-1516.7%	-$6K
Financing Cash Flow	$4.3M-82.6%	$24.5M-31.2%	$35.6M+212.2%	$11.4M-80.7%	$59.1M+70.7%	$34.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.8M+19.6%	-$8.4M-4.9%	-$8.0M+20.8%	-$10.1M+0.3%	-$10.2M-84.8%	-$5.5M+23.3%	-$7.2M-16.4%	-$6.2M
Capital Expenditures	$0	$0	$0-100.0%	$3K-80.0%	$15K-94.0%	$249K+48.2%	$168K+2300.0%	$7K
Free Cash Flow	-$6.8M+19.6%	-$8.4M-4.9%	-$8.0M+20.8%	-$10.2M+0.4%	-$10.2M-77.1%	-$5.8M+21.7%	-$7.4M-19.0%	-$6.2M
Investing Cash Flow	$0	$0	$0+100.0%	-$3K+80.0%	-$15K+94.0%	-$249K-48.2%	-$168K-2300.0%	-$7K
Financing Cash Flow	$13K-98.9%	$1.2M+266.4%	-$721K-104.0%	$18.0M+1065.0%	$1.5M-66.2%	$4.6M+912.7%	$450K-98.7%	$34.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TPST Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-2092150.0%-2091931.2pp	-218.8%-108.6pp	-110.2%+87.0pp	-197.2%-118.8pp	-78.4%	N/A
Return on Assets	-247.1%-146.3pp	-100.9%-43.7pp	-57.1%+20.3pp	-77.5%-38.8pp	-38.6%+45.4pp	-84.0%
Current Ratio	2.50+0.3	2.21-2.1	4.29-0.2	4.53+1.1	3.44-2.7	6.15
Debt-to-Equity	8464.50+8464.5	0.00-0.2	0.23-0.3	0.57+0.2	0.42+0.4	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-55.3%+25.1pp	-80.5%+17.1pp	-97.5%	N/A	-92.1%-35.6pp	-56.5%-18.2pp	-38.3%	N/A
Return on Assets	-20.5%+11.6pp	-32.1%+1.6pp	-33.8%	N/A	-31.2%-8.5pp	-22.7%-4.9pp	-17.8%	N/A
Current Ratio	2.30+0.2	2.12+0.4	1.70-0.5	2.21+0.5	1.69-0.5	2.17-1.0	3.13-1.2	4.29
Debt-to-Equity	1.70+0.2	1.50+1.1	0.38+0.4	0.000.0	0.00-0.1	0.12-0.1	0.20-0.0	0.23
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Radiopharm Theranostics Ltd RADX

$34.7M

Barinthus Biotherapeutics plc BRNS

$24.5M

Acrivon Therapeutics, Inc. ACRV

$58.9M

Plus Therapeutics Inc PSTV

$24.4M

Telomir Pharms TELO

$43.7M

Frequently Asked Questions

Is Tempest Therapeutics Inc profitable?

No, Tempest Therapeutics Inc (TPST) reported a net income of -$41.8M in fiscal year 2025.

What is Tempest Therapeutics Inc's EBITDA?

Tempest Therapeutics Inc (TPST) had EBITDA of -$26.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Tempest Therapeutics Inc's return on equity (ROE)?

Tempest Therapeutics Inc (TPST) has a return on equity of -2092150.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Tempest Therapeutics Inc's free cash flow?

Tempest Therapeutics Inc (TPST) generated -$27.3M in free cash flow during fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tempest Therapeutics Inc's operating cash flow?

Tempest Therapeutics Inc (TPST) generated -$26.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Tempest Therapeutics Inc's total assets?

Tempest Therapeutics Inc (TPST) had $16.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Tempest Therapeutics Inc's capital expenditures?

Tempest Therapeutics Inc (TPST) invested $435K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Tempest Therapeutics Inc spend on research and development?

Tempest Therapeutics Inc (TPST) invested $12.6M in research and development during fiscal year 2025.

How many shares does Tempest Therapeutics Inc have outstanding?

Tempest Therapeutics Inc (TPST) had 14M shares outstanding as of fiscal year 2025.

What is Tempest Therapeutics Inc's current ratio?

Tempest Therapeutics Inc (TPST) had a current ratio of 2.50 as of fiscal year 2025, which is generally considered healthy.

What is Tempest Therapeutics Inc's debt-to-equity ratio?

Tempest Therapeutics Inc (TPST) had a debt-to-equity ratio of 8464.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tempest Therapeutics Inc's return on assets (ROA)?

Tempest Therapeutics Inc (TPST) had a return on assets of -247.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Tempest Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Tempest Therapeutics Inc (TPST) had $7.7M in cash against an annual operating cash burn of $26.8M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Tempest Therapeutics Inc's Piotroski F-Score?

Tempest Therapeutics Inc (TPST) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tempest Therapeutics Inc's earnings high quality?

Tempest Therapeutics Inc (TPST) has an earnings quality ratio of 0.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Tempest Therapeutics Inc cover its interest payments?

Tempest Therapeutics Inc (TPST) has an interest coverage ratio of -128.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.